Loading
Adding relatlimab to adjuvant nivolumab did not reduce recurrence, so the LAG-3 combination stays a treatment for measurable disease.
RELATIVITY-098, trial NCT05002569 sponsored by Bristol Myers Squibb and published in 2025, found that adding the LAG-3 antibody relatlimab to adjuvant nivolumab did not reduce recurrence in resected stage III and IV melanoma, so the combination stays a treatment for measurable disease. It randomised 1,093 patients and showed no difference in recurrence-free survival, with overall survival not formally tested. OnCo links it to LAG-3 as a target, the relatlimab plus nivolumab and nivolumab records, Hussein A. Tawbi and a caution pairing about LAG-3 blockade outside active disease. Whether LAG-3 blockade needs an antigen-rich tumour to act on, echoing why neoadjuvant designs outperform adjuvant ones, is the question it raises.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,093 enrolled.
No difference; OS not formally tested
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Recurrence-free survivalprimary | Nivolumab + relatlimab | 547 | No difference; OS not formally tested | 1.01 (0.83 to 1.22) | 0.928 | link |
| Nivolumab | 546 | - |
Shares Caution: LAG-3 blockade outside active disease, Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable, Give immunotherapy in the morning, Randomised trials of stopping immunotherapy after one year versus continuing and the tag failure.
Shares Melanoma, Immune checkpoint inhibitors and the tag failure.
Shares Melanoma and the tag failure.
Shares Immune checkpoint inhibitors and the tag failure.
Shares Immune checkpoint inhibitors and the tag failure.
Shares Immune checkpoint inhibitors and the tag failure.
Shares Immune checkpoint inhibitors and the tag failure.